检测系统性硬化症相关间质性肺病的筛查工具:ILD-RISC评分
为填补系统性硬化症相关间质性肺病(SSc-ILD)高分辨率CT(HRCT)筛查工具的空白,研究开发了ILD-RISC评分以指导医生开具HRCT,尤其关注随访。该评分在533例推导队列中建立,曲线下面积79.1%(75.3-83.0%),评分≥0.3时敏感性85.6%、特异性53.6%,并在247例验证队列中确认;在819例基线HRCT阴性患者中,170例发展为SSc-ILD,近50%的随访中评分较低,支持减少HRCT检查。
要点
- ILD-RISC评分包含FVC%、DLCO/SB%、曾出现指端溃疡、年龄和SSc自身抗体。
- 评分≥0.3时敏感性85.6%、特异性53.6%,验证队列确认。
- 基线HRCT阴性患者随访中近50%评分较低,支持减少HRCT。
核心结论
- ILD-RISC评分已开发并验证用于预测SSc-ILD的存在,可能有助于决定随访时何时开具HRCT,从而降低成本和辐射暴露,在资源有限时诊断SSc也可参考。
研究设计与样本
- 采用名义群体技术选择变量,基于推导队列基线访视进行多变量逻辑回归(后退法)开发ILD-RISC评分,从ROC曲线确定偏向敏感性>85%的截断值,在独立横断面队列中验证,并在基线HRCT阴性的特定SSc队列中纵向应用。
主要发现
- 推导队列533例患者中测试了13个与HRCT上SSc-ILD存在相关的变量。
- ILD-RISC评分对HRCT上SSc-ILD存在的曲线下面积为79.1%(75.3-83.0%)。
- ILD-RISC评分≥0.3的敏感性为85.6%,特异性为53.6%,在验证队列(247例患者)中得到确认。
- 819例基线HRCT阴性患者中170例发展为SSc-ILD,近50%的随访访视中检测到低ILD-RISC评分,支持节省HRCT。
关键数值与推荐
- ILD-RISC评分包含FVC%、DLCO/SB%、曾出现指端溃疡、年龄和SSc自身抗体。
- ILD-RISC评分≥0.3的敏感性85.6%、特异性53.6%。
- 对HRCT上SSc-ILD存在的曲线下面积为79.1%(75.3-83.0%)。
临床怎么用
- ILD-RISC评分可能有助于决定随访时何时开具HRCT,从而降低成本和辐射暴露,在资源有限时诊断SSc也可参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: As a screening tool for the presence of systemic sclerosis-associated interstitial lung disease (SSc-ILD) on high-resolution computed tomography (HRCT) is missing, we aimed to develop the ILD-RISC score, a risk algorithm to guide physicians in ordering HRCTs, with specific focus on follow-up visits. METHODS: The nominal group technique was used to select items for the multivariable logistic regression with backward selection. The ILD-RISC score was developed from baseline visits of the derivation cohort. After identifying a cut-off favoring sensitivity >85% from the ROC curve, it was validated in a separate cross-sectional cohort, and then applied longitudinally in a specific SSc cohort with negative baseline HRCT. RESULTS: In the derivation cohort (533 patients), 13 variables associated with the presence of SSc-ILD on HRCT were tested. The ILD-RISC score, including FVC%, DLCO/SB%, digital ulcers ever, age and SSc autoantibodies, showed an area under the curve of 79.1% (75.3-83.0%) for the presence of SSc-ILD on HRCT. An ILD-RISC score ≥0.3 had sensitivity 85.6% and specificity 53.6%, as confirmed in the validation cohort (247 patients). Among 819 patients with negative baseline HRCT, 170 developed SSc-ILD: a low ILD-RISC score was detected in almost 50% of the follow-up visits, supporting the sparing of HRCTs. CONCLUSION: The ILD-RISC score was developed and validated to predict the presence of SSc-ILD. Thus, the ILD-RISC score may help to decide when to order HRCTs at follow-up, allowing the reduction of costs and radiation exposure, but also at the time of SSc diagnosis when resources are limited.
引用
- Bruni C, Tofani L, Fretheim H, et al. A screening tool to detect interstitial lung disease in systemic sclerosis: the ILD-RISC score. Rheumatology (Oxford). 2025. PMID: 40811030. doi:10.1093/rheumatology/keaf445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。